Gomez-Peralta, FCarrasco-Sanchez, F JPerez, AEscalada, JAlvarez-Guisasola, FMiranda-Fernandez-Santos, CMediavilla-Bravo, J JGomez-Huelgas, Ricardo2023-05-032023-05-032022-10-01Gómez-Peralta F, Carrasco-Sánchez FJ, Pérez A, Escalada J, Álvarez-Guisasola F, Miranda-Fernández-Santos C, et al. Executive summary on the treatment of type 2 diabetes mellitus in elderly or frail individuals. 2022 update of the 2018 consensus document "Treatment of type 2 diabetes mellitus in the elderly". Rev Clin Esp (Barc). 2022 Oct;222(8):496-499http://hdl.handle.net/10668/22489The population with type 2 DM (DM2) is highly heterogeneous, representing an important challenge for healthcare professionals. The therapeutic choice should be individualized, considering the functional status, frailty, the occurrence of comorbidities, and the preferences of patients and their caregivers. New evidence on the cardiovascular and renal protection of specific therapeutic groups and on the usefulness of new technologies for DM2 management, among other aspects, warrant an update of the consensus document on the DM2 in the elderly that was published in 2018.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Antidiabetic treatmentDiabetes mellitus tipo 2Edad avanzadaElderlyFragilidadFrailtyTechnology applied to diabetesTecnología aplicada a la diabetesTratamiento antidiabéticoType 2 diabetes mellitusAgedComorbidityConsensusDiabetes MellitusDiabetes Mellitus, Type 2Frail ElderlyFrailtyHumansresearch article35753941open accessEstado FuncionalCuidadoresFragilidadFactores ProtectoresAtención a la Salud10.1016/j.rceng.2022.03.0052254-8874https://doi.org/10.1016/j.rceng.2022.03.005